

## 1169082 B.C. LTD. ANNOUNCES ASSIGNMENT OF LETTER OF INTENT TO ACQUIRE HEMAGENETIC RESEARCH GROUP

**Vancouver, B.C., April 23, 2019** – **1169082 B.C. Ltd.** (the “Company” or “082BC”) announces that it has signed an assignment agreement with Hemagenetics Technologies Corp. (“HTC”), 082BC’s parent company, pursuant to which HTC has assigned its rights and interest in a letter of intent to acquire the HemaGenetic Research Group (“HRG”) and related intellectual property (IP) owned and operated by Dr. Haixing Chen.

The Company anticipates negotiating terms and closing on a definitive acquisition agreement with HRG on or before Friday, May 17, 2019.

### Planned Acquisition Terms

082BC will issue a total 50,000,000 common shares with a fair market value of \$25,000,000 (the “Purchase Price”) to Dr. Chen and HRG to acquire 100% ownership interest in HRG and the IP subject to completion of due diligence.

Other key terms include the Company raising financing to meet IP development plans as follows;

- (i) \$4,000,000 in financing / working capital on or before June 30, 2019;
- (ii) an additional \$4,000,000 in financing / working capital on or before September 30, 2019; and
- (iii) complete current and planned transactions under the Company’s plans of arrangement.

A 1,000,000 common share finder’s fee will also be issued and paid in conjunction with closing of this acquisition.

### About HRG

HRG is a private research group that has developed patented gene technology for the delivery of therapeutic proteins through patients’ bone marrow via stem cell in vitro with 100% delivery upon rupture of red blood cells at their end of life cycle (the “IP”). The IP is targeted towards the \$150+ billion global therapeutic protein market that is anticipated to reach \$217.6 billion by 2023<sup>1</sup>.

### 1169082 B.C. LTD.

On behalf of the Board of Directors

Ron Ozols, V.P. Communications  
Contact: [pubcosrvc@outlook.com](mailto:pubcosrvc@outlook.com)

<sup>1</sup> [Allied Market Research](#)

*Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of 082BC. Forward-looking information is based on certain key expectations and assumptions made by the management of 082BC. Although 082BC believes that the expectations and assumptions on which such forward-looking information is based on are reasonable, undue reliance should not be placed on the forward-looking information because 082BC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. 082BC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.*